Navigation Links
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Date:1/16/2017

SOUTH SAN FRANCISCO, Calif., Jan. 16, 2017 /PRNewswire/ -- Rigel Pharmaceuticals (Nasdaq: RIGL) today announced that on January 3, 2017 and January 16, 2017 the Compensation Committee of Rigel's Board of Directors approved the grant of inducement stock options to purchase an aggregate of 214,000 shares of common stock to four new employees. These awards were granted pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, as amended, as an inducement material to the new employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4).

Rigel granted stock options to purchase shares of Rigel's common stock to (i) three of the employees with an exercise price of $2.38 per share, the closing price of Rigel's common stock on December 30, 2016, the first trading date prior to January 3, 2017, the effective date of such grants and (ii) one employee with an exercise price of $2.51 per share, the closing price of Rigel's common stock on January 13, 2017, the first trading date prior to January 16, 2017 the effective date of such grant. The stock options vest as follows: certain of the shares of common stock subject to the award vest in equal monthly installments over a two period subject to the achievement of one or more performance conditions and certain of the shares of common stock subject to the award vest in equal monthly installments over a four year period, with one-fourth of the shares subject to the award vesting on the first anniversary of the vesting commencement date.

Rigel is providing this information in accordance with NASDAQ Listing Rule 5635(c)(4).

About Rigel (www.rigel.com)

Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of novel, targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's current clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor in a number of indications. The company completed and reported results from two Phase 3 clinical studies of fostamatinib in chronic immune thrombocytopenia (ITP) in August and October 2016. Rigel is also conducting a Phase 2 clinical trial with fostamatinib in autoimmune hemolytic anemia (AIHA) and a Phase 2 clinical trial for IgA nephropathy (IgAN). In addition, Rigel has two oncology product candidates in Phase 1 development with partners BerGenBio AS and Daiichi Sankyo.

Contact: Raul Rodriguez
Phone: 650.624.1302
Email: invrel@rigel.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-300391187.html


'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Rigel Names Anne-Marie Duliege, M.D., M.S. As Chief Medical Officer
2. Rigel Announces Fourth Quarter and Year End 2015 Financial Results
3. Rigel to Present at Cowen and Company 36th Annual Health Care Conference
4. Rigel Initiates Phase 2 Clinical Trial Of Fostamatinib In Autoimmune Hemolytic Anemia
5. Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP (FIT)
6. Rigel Reviews Recent Progress and Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco
7. Rigel Announces Third Quarter 2015 Financial Results
8. Rigel Announces Conference Call and Webcast to Report Third Quarter 2015 Financial Results
9. Rigel and Aclaris Therapeutics International Sign License Agreement for JAK Inhibitors to Treat Skin Disorders
10. Rigel Granted Orphan Drug Designation for Fostamatinib in ITP
11. Rigel Announces Second Quarter 2015 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2019)... JOSE, Calif. (PRWEB) , ... July 17, 2019 , ... ... today continues its rapid expansion with the addition of three new executive hires: CFO ... VP of Software Engineering, Fernando Cruz (from Rappi, Inc., Apple, Inc.). , The ...
(Date:7/17/2019)... , ... July 17, 2019 , ... ... DFree ®, the first wearable for urinary incontinence, will be highlighted at ... Stanford, CA, on July 26, 2019. The Innovation Showcase recognizes startups with Japanese ...
(Date:7/17/2019)... ... July 17, 2019 , ... On July 1, 2019, Oklahoma Magazine named Whole Leaf ... For the past 20 years Oklahoma Magazine has released its Best of the Best to ... the Best award recognizes Whole Leaf for having several strains of marijuana with varying levels ...
Breaking Medicine Technology:
(Date:7/17/2019)... LAS VEGAS (PRWEB) , ... July 17, 2019 ... ... an innovative thought leader offering fresh, insightful, honest perspectives on today’s issues affecting ... Workshop from Noon, 12 p.m. PST on Saturday, July 20, 2019. , ...
(Date:7/17/2019)... ... July 17, 2019 , ... The ... online Family Nurse Practitioner program. The honor is given to distance learning courses ... , The Catalyst Awards honor institutions from around the world that produce exemplary ...
(Date:7/17/2019)... ... 17, 2019 , ... Becker's Healthcare is pleased to recognize ... men and women included on this list lead organizations regularly recognized for patient ... well as the construction of satellite clinics and strategic partnerships with local healthcare ...
(Date:7/17/2019)... ... July 17, 2019 , ... ICD10monitor, an online ... coding set, is launching an exclusive educational webcast subscription service featuring 40 original ... officials announced this week. , The ICD10monitor webcast portfolio already includes sought-after ...
(Date:7/17/2019)... ... July 17, 2019 , ... This past Saturday, Monarch Dental® ... Everyone Foundation . Over 50 underserved patients were welcomed at the Mesquite office to ... celebrating the summer season. Individuals were referred to the event through local nonprofit organizations ...
Breaking Medicine News(10 mins):